CAPR: FDA Plans Advisory Meeting
Capricor Therapeutics' BLA for Deramiocel is set to be discussed by the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee
S. Food and Drug Administration (FDA) is planning to convene an advisory committee meeting to discuss the Company's Biologics License Application (BLA) seeking approval of Deramiocel, an investigational cell therapy for the treatment of Duchenne muscular dystrophy (DMD). 0), the key secondary cardiac endpoint (LVEF), and all other Type I error-controlled secondary endpoints. The date for the Advisory Committee meeting is July 29, 2026, and the meeting will be available for live streaming.